ProCE Banner Activity

CE / CME

Measurable Residual Disease in ALL: Proof of the Principle Transforming Care for Patients With Hematologic Malignancies

This expert panel examines the importance of incorporating MRD testing in ALL and the use of blinatumomab in MRD-positive ALL after CR to provide your patients with better outcomes

Pharmacists : 1.25 contact {hours} ({0.125} CEUs)

Physicians : maximum of 1.25 AMA PRA Category 1 {Credits}

Released: November 01, 2018

Expiration: November 08, 2019

No longer available for credit.
Begin Activity

Share

Faculty

Elias Jabbour

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Joseph D. Khoury

Joseph D. Khoury, MD

Professor
Department of Hematology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Aaron C. Logan

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Adaptive Biotechnologies

Amgen, Inc.

Partners

GRACE

ProCE Banner

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with acute lymphoblastic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss when to test for MRD in patients with ALL
  • Describe the different tests for MRD and how to obtain them
  • Work with pathologists to determine MRD positivity, based on the test used, in patients with ALL
  • Select appropriate treatment options for patients with MRD-positive ALL
  • Answer patient questions regarding the use of MRD to diagnose disease that is present after induction that requires additional treatment in ALL and soon in other diseases

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director Disclosure

Program Director

Elias Jabbour, MD

Assistant Professor
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Elias Jabbour, MD, has no real or apparent conflicts of interest to report.

Faculty Disclosure

Primary Author

Joseph D. Khoury, MD

Professor
Department of Hematology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Joseph D. Khoury, MD, has no real or apparent conflicts of interest to report.

Aaron C. Logan, MD, PhD

Associate Professor
Division of Hematology and Blood and Marrow Transplantation
University of California, San Francisco
San Francisco, California

Aaron C. Logan, MD, PhD, has disclosed that he has received consulting fees from Amgen.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-420-H01-P

Type of Activity: Application

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 01, 2018, through November 08, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge and competence regarding the use of measurable residual disease in acute lymphoblastic leukemia and other hematologic malignancies.